NewKerala.com

India's Healthcare Q4 Outlook: Single-Digit Revenue Growth, Margin Pressures

Healthcare firms in India are projected to deliver high single-digit revenue growth for the fourth quarter of FY26. However, EBITDA margins are set for a material correction, with median net earnings expected to decline by 14% year-on-year. The primary driver for this earnings drop is the loss of exclusivity for gRevlimid, significantly impacting major players like Dr. Reddy's. Meanwhile, regulatory oversight is increasing for weight-loss and diabetes drugs like GLP-1 agonists as they gain popularity in the domestic market.

Key Points: India Healthcare Firms Face Single-Digit Q4 Growth, Margin Correction

  • Single-digit revenue growth expected
  • EBITDA margins to correct materially
  • Net earnings may fall 14%
  • gRevlimid exclusivity loss a key driver
  • US-Iran conflict adds cost pressure
2 min read

Healthcare firms in India likely to deliver single-digit revenue growth in Q4

Indian pharma companies may see high single-digit revenue growth in Q4 FY26, but EBITDA margins and net earnings are expected to decline sharply.

"Median growth is estimated at 12 per cent for revenue and 3.6 per cent for EBTIDA, with net earnings likely witnessing a 14 per cent decline - Systematix Report"

New Delhi, April 15

Healthcare companies in India are expected to deliver high single-digit revenue growth in the fourth quarter of FY26, a report showed on Wednesday.

However, EBITDA margins will materially be corrected, according to the report by Systematix.

"Median growth is estimated at 12 per cent for revenue and 3.6 per cent for EBTIDA, with net earnings likely witnessing a 14 per cent decline, the report mentioned.

The primary driver of this on-year decline in net earnings is loss of exclusivity in gRevlimid, with the impact most pronounced for Dr. Reddy's, Zydus, Cipla and Sun Pharma.

Cipla may additionally bear the brunt of supply disruption in Lanreotide, said the report.

Meanwhile, Lupin and Zydus may see some margin pressure due to mirabegron-related (royalty payments) settlements, the report said.

The quarter is likely to reflect mixed implications from the US-Iran conflict, as higher freight and raw material (RM) costs could partially offset the favorable impact of USD/INR appreciation.

"If the conflict persists, these cost pressures could intensify in the coming quarters. Active pharmaceutical ingredient (API) manufacturers are likely to pass on the RM inflation and may even raise prices, as formulation manufacturers look to expand their RM inventories," the findings showed.

Dr. Reddy's could see the steepest earnings decline, as the disproportionate contribution of gRevlimid in its earnings would taper off completely.

Any potential shelf stock adjustments related to gRevlimid could further dent the company's earnings, the report mentioned.

Meanwhile, India's drug regulators are stepping up oversight of fast-growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.

The move comes as the Indian Pharmacopoeia Commission (IPC), which functions under the Ministry of Health, has been tasked with systematically collecting and analysing adverse event reports linked to these drugs.

The initiative aims to strengthen post-marketing surveillance and ensure that any safety concerns are quickly identified and addressed.

Officials indicated that the step is part of a broader regulatory push to keep pace with the rapid uptake of these therapies, especially as affordability improves.

- IANS

Share this article:

Reader Comments

P
Priya S
The increased oversight on weight-loss drugs is a very good step 👍. With cheaper generics coming, everyone will start using them. We need strict monitoring for side effects. Health should not be compromised for quick fixes.
A
Aman W
Single-digit growth in revenue but a double-digit decline in earnings? That doesn't sound sustainable. It shows how dependent our companies are on a few blockbuster drugs in the US market. Time to diversify the portfolio and focus more on domestic innovation.
S
Sarah B
The mention of the US-Iran conflict impacting costs is a stark reminder. Global instability directly hits our medicine supply chains and ultimately prices for patients. Hope for a peaceful resolution soon.
K
Karthik V
While the report highlights challenges, let's not forget the resilience of Indian pharma. They've navigated patent cliffs before. The focus on post-marketing surveillance for new therapies is a proactive move that builds long-term trust.
N
Nisha Z
As an investor, this quarterly outlook is a reality check. The golden period of easy generic money in the US might be slowing. Need to look at companies with strong domestic brands and a pipeline in complex generics or specialty drugs.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50